Report of Foreign Issuer (6-k)
April 28 2015 - 6:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2015
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 28 April 2015
|
|
|
|
|
ASX:NRT
NASDAQ:NVGN
Novogen Ltd (Company)
ABN 37 063 259 754
Capital Structure
Ordinary Shares on issue:
343 M
Board of
Directors Dr Graham Kelly
Chairman & Executive Director
Steve Coffey Non Executive Director
John OConnor
Non Executive Director
Prof Peter Gunning Non Executive Director |
|
MARKET RELEASE 28 April
2015 NOVOGEN REGAINS FULL COMPLIANCE WITH NASDAQ LISTING
RULE Sydney, Australia, 28 April 2015: US-Australian
drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (Company), announced today that it received a letter from NASDAQ informing it that it had regained full compliance with NASDAQ Listing Rule 5550(b) (Listing Rule).
In November 2014, the Company received a deficiency notice from NASDAQ, requesting the
Company to submit a plan to regain compliance with the Listing Rule, which requires either (i) a minimum of $2,500,000 in stockholders equity as of June 30, 2014; (ii) at least $35,000,000 market value of listed securities, or (iii) at least
$500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.
Further to lodgement of its plan to regain compliance, NASDAQ granted an extension to the Company in January 2015.
The recent growth in the Companys market value, as well as the substantial increase
of its assets with the current capital-raising program, has allowed the Company to regain compliance with the Listing Rule.
Graham Kelly, Novogen Group CEO and Executive Chairman, said, Novogen regards itself as a joint US-Australian company. Roughly half of our shareholders
are US residents. We have a joint venture company with one of the leading universities in the US. We are conducting increasing collaborations with leading US research institutions and hospitals as our drug technologies get better appreciated. The US
eventually will be the leading market for our drug candidates. Maintaining our NASDAQ listing is vital to us.
About Novogen
Novogen is a public, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange (NRT) and NASDAQ
(NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed
to kill the full heterogeneity of cells within a tumor, but with particular activity against the slowly-dividing, less differentiated cancer stem (tumor-initiating) cell. The ATM compounds target the micro-filament component of the cancer
cells cytoskeleton and have been designed to combine with anti-microtubule drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton. The Company pipeline currently comprises two SBP drug
candidates (TRXE-002, TRXE-009) and one ATM drug candidate (Anisina). |
For more information, please visit www.novogen.com
|
|
|
Corporate Contact Dr. Graham Kelly
Executive Chairman & CEO Novogen Group
Graham.Kelly@novogen.com +61 (0) 2 9472 4100 |
|
Media Enquiries Cristyn Humphreys
Chief Operating Officer Novogen Group
Cristyn.Humphreys@novogen.com +61 (0) 2 9472
4111 |
Forward Looking Statement
All statements other than statements of historical fact included in this announcement including, without limitation, statements regarding future plans and
objectives of Novogen Limited (Novogen) are forward-looking statements. When used in this announcement, forward-looking statements can be identified by words such as may, could, should,
would, believes, estimates, targets, expects or intends and other similar words that involve risks and uncertainties.
Such statements relate to future events and expectations and as such involve known and unknown risks and uncertainties. These risks and uncertainties
include, among other things, market conditions, weather risks, economic and political risks.
These statements are based on an assessment of present
economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this announcement, are expected to take place. Such forward-looking statements are not guarantees of future performance and
involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Novogen, its directors and management, which could cause Novogens actual results to differ materially from the
results expressed or anticipated in these statements.
Novogen cannot and does not give any assurance that the results, performance or achievements
expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements. Actual results, actions, and developments may
differ materially from those expressed or implied by those forward-looking statements depending on a variety of factors.
Novogen does not undertake
to update or revise forward- looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this announcement, except
where required by applicable law and stock exchange listing requirements.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From May 2024 to Jun 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2023 to Jun 2024